Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01031420 · ClinicalTrials.gov registry record · Phase 2
Dose Dense MVAC for Muscle Invasive Bladder Cancer
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT01031420 is a Phase 2 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 54 participants.
The verdict
NCT01031420, a Phase 2 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
Standard treatment for early stage bladder cancer is chemotherapy with methotrexate (M), vinblastine (V), adriamycin (A), and cisplatin (C) followed by surgical removal of any remaining cancer and the bladder with the intent of cure. The M V chemotherapy is usually given every 14 days with the AC given along each 28 days. This study looks at giving the same drugs at the same doses closer together, all drugs every 14 days, with the support of growth factor medication to promote growth of the white blood cells and platelets and allow chemotherapy to be finished sooner and surgery to be done sooner.
Interventions
- DRUG single arm dose dense MVAC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2009-12-07 |
| Est. Completion | 2013-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01031420
The ClinicalTrials.gov registry entry for NCT01031420 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which single arm dose dense MVAC is the first listed.
NCT01031420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01031420 about?
NCT01031420 is a clinical study titled "Dose Dense MVAC for Muscle Invasive Bladder Cancer". Standard treatment for early stage bladder cancer is chemotherapy with methotrexate (M), vinblastine (V), adriamycin (A), and cisplatin (C) followed by surgical removal of any remaining cancer and the bladder with the intent of cure. The M V chemotherapy is usually given every 14 days with the AC gi...
What is the current status of trial NCT01031420?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2009-12-07. Estimated completion is 2013-08-07.
What interventions are being tested in trial NCT01031420?
The interventions under investigation include: single arm dose dense MVAC (DRUG).
Who is sponsoring clinical trial NCT01031420?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.